Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
Authors
Keywords
Cardiovascular complications, Vascular dysfunction, Cognitive decline, Oxidative stress, Inflammation
Journal
Cardiovascular Diabetology
Volume 13, Issue 1, Pages -
Publisher
Springer Nature
Online
2014-10-25
DOI
10.1186/s12933-014-0148-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis
- (2014) A. Liakos et al. DIABETES OBESITY & METABOLISM
- SGLT2 inhibitors in the treatment of type 2 diabetes
- (2014) Farhad M. Hasan et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Rosuvastatin Ameliorates Early Brain Injury after Subarachnoid Hemorrhage via Suppression of Superoxide Formation and Nuclear Factor-Kappa B Activation in Rats
- (2014) Ken Uekawa et al. Journal of Stroke & Cerebrovascular Diseases
- Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors
- (2014) Raymond V. Oliva et al. Journal of the American Society of Hypertension
- Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice
- (2014) Naoto Terami et al. PLoS One
- Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
- (2014) Anthony H Barnett et al. Lancet Diabetes & Endocrinology
- Effect of Strict Glycemic Control in Patients With Diabetes Mellitus on Frequency of Macrovascular Events
- (2013) Amita Singh et al. AMERICAN JOURNAL OF CARDIOLOGY
- Apoptosis Signal–Regulating Kinase 1 Is a Novel Target Molecule for Cognitive Impairment Induced by Chronic Cerebral Hypoperfusion
- (2013) Kensuke Toyama et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function indb/dbmice
- (2013) T Nagata et al. BRITISH JOURNAL OF PHARMACOLOGY
- Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control
- (2013) Martin Ridderstråle et al. Cardiovascular Diabetology
- The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study
- (2013) Arne Ring et al. Cardiovascular Diabetology
- Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials
- (2013) M. Monami et al. DIABETES OBESITY & METABOLISM
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differential central pathology and cognitive impairment in pre-diabetic and diabetic mice
- (2013) Juan Jose Ramos-Rodriguez et al. PSYCHONEUROENDOCRINOLOGY
- Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions
- (2013) Geert Jan Biessels et al. Lancet Diabetes & Endocrinology
- Effects of SGLT2 inhibitors on cardiovascular outcomes
- (2012) Celine Foote et al. Diabetes & Vascular Disease Research
- SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
- (2012) Ele Ferrannini et al. Nature Reviews Endocrinology
- Sodium-Glucose Cotransporter Inhibition Prevents Oxidative Stress in the Kidney of Diabetic Rats
- (2012) Horacio Osorio et al. Oxidative Medicine and Cellular Longevity
- Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat
- (2011) Scott C. Thomson et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Decreased Cerebrovascular Brain-Derived Neurotrophic Factor-Mediated Neuroprotection in the Diabetic Brain
- (2011) D. Navaratna et al. DIABETES
- Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats
- (2011) L. Thomas et al. DIABETES OBESITY & METABOLISM
- Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
- (2011) R. Grempler et al. DIABETES OBESITY & METABOLISM
- Attenuation of Brain Damage and Cognitive Impairment by Direct Renin Inhibition in Mice With Chronic Cerebral Hypoperfusion
- (2011) Yi-Fei Dong et al. HYPERTENSION
- Cognitive and Emotional Alterations Are Related to Hippocampal Inflammation in a Mouse Model of Metabolic Syndrome
- (2011) Anne-Laure Dinel et al. PLoS One
- Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice
- (2010) Masaya Fukuda et al. JOURNAL OF HYPERTENSION
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
- (2010) The Emerging Risk Factors Collaboration LANCET
- Insulin metabolism and the risk of Alzheimer disease: The Rotterdam Study
- (2010) E. M. C. Schrijvers et al. NEUROLOGY
- Insulin resistance is associated with the pathology of Alzheimer disease: The Hisayama Study
- (2010) T. Matsuzaki et al. NEUROLOGY
- Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes
- (2009) Y. F. Dong et al. DIABETOLOGIA
- Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons
- (2008) Alexis M Stranahan et al. NATURE NEUROSCIENCE
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation